Rabbit anti-Human CAV3 Polyclonal Antibody | anti-CAV3 antibody

CAV3, NT (Caveolin-3, M-caveolin) (MaxLight 405)

Cat. Num. AAA6467779

• Gene Names: CAV3; LQT9; VIP21; LGMD1C; VIP-21
• Reactivity: Human
• Applications: Immunohistochemistry, Western Blot
• Purity: Purified by Ammonium Sulfate Precipitation.
• Synonyms: CAV3; Polyclonal Antibody; NT (Caveolin-3; M-caveolin) (MaxLight 405); anti-CAV3 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes human CAV3.
• Purity/Purification: Purified by Ammonium Sulfate Precipitation.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight405.

• Applicable Applications for anti-CAV3 antibody: Immunohistochemistry (IHC), FLISA, Western Blot (WB)
• Application Notes: IHC: 1:10-1:50; FLISA: 1:1,000; WB: 1:50-1:100; Applications are based on unconjugated antibody.
• Immunogen: Synthetic peptide selected from the N-terminal region of human CAV3 (KLH).
• Conjugate: MaxLight405
• Note: Preservative Free
• Preparation and Storage: Store product at 4 degree C in the dark. DO NOT FREEZE! Stable at 4 degree C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight405 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Western Blot (WB)

(Western blot analysis of CAV3 antibody (N-term) in 293 cell line lysates (35ug/lane). CAV3 (arrow) was detected using the purified Pab.)

Immunohistochemistry (IHC)

(Formalin-fixed and paraffin-embedded human Skeletal muscle reacted with CAV3 Antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.)

Flow Cytometry (FC/FACS)

(Flow cytometric analysis of 293 cells using CAV3 Antibody (N-term)(bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.)

Product Categories/Family for anti-CAV3 antibody

Antibodies; Membrane Proteins

References

1. Garg, V., Biochem. Biophys. Res. Commun. 385(3), 472-477 (2009). 2. Cai, C., . Biol. Chem. 284(23), 15894-15902 (2009).

NCBI and Uniprot Product Information

• NCBI GI #: 4502589
• NCBI GeneID: 859
• NCBI Accession #: NP_001225
• NCBI GenBank Nucleotide #: NM_001234
• UniProt Accession #: P56539; Q3T1A4; A8K777
• Molecular Weight: 17,259 Da
• NCBI Official Full Name: caveolin-3
• NCBI Official Synonym Full Names: caveolin 3
• NCBI Official Symbol: CAV3
• NCBI Official Synonym Symbols: LQT9; VIP21; LGMD1C; VIP-21
• NCBI Protein Information: caveolin-3; M-caveolin
• UniProt Protein Name: Caveolin-3
• Protein Family: Caveolin
• UniProt Gene Name: CAV3
• UniProt Entry Name: CAV3_HUMAN

Uniprot Description

caveolin-3: May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. May also regulate voltage-gated potassium channels. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress. Defects in CAV3 are the cause of limb-girdle muscular dystrophy type 1C (LGMD1C). LGMD1C is a myopathy characterized by calf hypertrophy and mild to moderate proximal muscle weakness. LGMD1C inheritance can be autosomal dominant or recessive. Defects in CAV3 are a cause of hyperCKmia (HYPCK). It is a disease characterized by persistent elevated levels of serum creatine kinase without muscle weakness. Defects in CAV3 are a cause of rippling muscle disease (RMD). RMD is a rare disorder characterized by mechanically triggered contractions of skeletal muscle. In RMD, mechanical stimulation leads to electrically silent muscle contractions that spread to neighboring fibers that cause visible ripples to move over the muscle. Defects in CAV3 are a cause of familial hypertrophic cardiomyopathy (CMH); also designated FHC or HCM. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. Defects in CAV3 are the cause of long QT syndrome type 9 (LQT9). Long QT syndromes are heart disorders characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to excercise or emotional stress. They can present with a sentinel event of sudden cardiac death in infancy. Defects in CAV3 can be a cause of sudden infant death syndrome (SIDS). SIDS is the sudden death of an infant younger than 1 year that remains unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of clinical history. Pathophysiologic mechanisms for SIDS may include respiratory dysfunction, cardiac dysrhythmias, cardiorespiratory instability, and inborn errors of metabolism, but definitive pathogenic mechanisms precipitating an infant sudden death remain elusive. Long QT syndromes-associated mutations can be responsible for some SIDS cases. Defects in CAV3 are the cause of myopathy distal Tateyama type (MPDT). A disorder characterized by progressive muscular atrophy and muscle weakness beginning in the hands, the legs, or the feet. Muscle atrophy may be restricted to the small muscles of the hands and feet. Belongs to the caveolin family.

Protein type: Dystrophin complex; Extracellular matrix; Motility/polarity/chemotaxis; Cell development/differentiation

Chromosomal Location of Human Ortholog: 3p25

Cellular Component: Golgi membrane; dystrophin-associated glycoprotein complex; cell surface; endoplasmic reticulum; T-tubule; plasma membrane; caveola; Z disc; neuromuscular junction; sarcolemma; vesicle; lipid raft

Molecular Function: protein C-terminus binding; protein binding; sodium channel regulator activity; calcium channel regulator activity; protein complex binding; protein complex scaffold; nitric-oxide synthase binding; potassium channel inhibitor activity; alpha-tubulin binding

Biological Process: negative regulation of MAP kinase activity; muscle development; positive regulation of microtubule polymerization; T-tubule organization and biogenesis; negative regulation of cell size; glucose homeostasis; cytoplasmic microtubule organization and biogenesis; regulation of heart contraction; muscle maintenance; protein localization; elevation of cytosolic calcium ion concentration; cardiac muscle cell development; regulation of transforming growth factor beta receptor signaling pathway; plasma membrane organization and biogenesis; regulation of skeletal muscle contraction; positive regulation of cell proliferation; cell growth; cell differentiation; myoblast fusion; regulation of nerve growth factor receptor activity; negative regulation of calcium ion transport; negative regulation of nitric-oxide synthase activity; negative regulation of MAPKKK cascade; regulation of heart rate; actin filament organization; endocytosis; regulation of protein kinase B signaling cascade; nucleus localization; cholesterol homeostasis; regulation of membrane potential; triacylglycerol metabolic process; plasma membrane repair; negative regulation of protein kinase activity; lipid raft organization and biogenesis

Disease: Creatine Phosphokinase, Elevated Serum; Long Qt Syndrome 9; Rippling Muscle Disease; Muscular Dystrophy, Limb-girdle, Type 1c; Myopathy, Distal, Tateyama Type; Cardiomyopathy, Familial Hypertrophic, 1